"We are very excited that our MEDIROM MOTHER Labs subsidiary has received such significant validation from strategic partners as our lead investor NFES Technologies Inc. as well as M3,Inc and Elematec Corporation. The pre money valuation of 9 billion yen is approximately multiples of MEDIROM's current NASDAQ listing market capitalization which I believe further validates our technology, business model and growth potential.” said Kouji. The MOTHER Bracelet ® is currently in commercialization. From July 1, 2024 through October 31, 2024, MEDIROM MOTHER Labs received purchase orders for an aggregate of over 25,000 units from its B2B sales channel. "We believe the MOTHER Bracelet ® to be the world's first fitness tracker that requires no electric charging by utilizing an innovative technology that enables the user's body heat to generate electricity. We co-developed it with Matrix Industries, based in Silicon Valley and believe its features are cutting-edge technology with rich features and ease of use to track fitness levels, sleep patterns, pulse and body temperature We will continue to target markets such as hospitals, nursing homes and gyms, where such data is vital,” said Yoshio Uekusa, CEO of MEDIROM MOTHER Labs. ABOUT MEDIROM MOTHER Labs Inc. A subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) ("MEDIROM”), MEDIROM Mother Labs Inc. focuses on the health-tech sector. The company's core activities include the "Specific Health Guidance Program" offered through the "Lav" health application and development and sales of the 24/7 recharge-free MOTHER Bracelet ®︎ smart tracker. By leveraging the features of the recharge-free MOTHER Bracelet ®︎ , MOTHER Labs offers customizable health management solutions across diverse sectors, including caregiving, logistics, manufacturing, and similar industries. Forward-Looking Statements Regarding MEDIROM and MOTHER Labs Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about MEDIROM's possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as "may,” "will,” "should,” "design,” "target,” "aim,” "hope,” "expect,” "could,” "intend,” "plan,” "anticipate,” "estimate,” "believe,” "continue,” "predict,” "project,” "potential,” "goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to MEDIROM's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause MEDIROM's actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond MEDIROM's control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects MEDIROM's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MEDIROM's operations, results of operations, growth strategy and liquidity. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release include: MEDIROM Healthcare Technologies Inc. NASDAQ Symbol: MRM Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan Web https://medirom.co.jp/en Contact: [email protected] MEDIROM MOTHER Labs Inc. Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan For more information visit: https://mother-bracelet.com
Creative Biolabs: A Specialist in Lipid-Based Drug Delivery System Development
Iceland votes for new a parliament after coalition dissolvedThe Ceylon Chamber of Commerce has announced the 24th edition of the Sri Lanka Economic Summit (SLES), scheduled for January 28th and 29th, 2025, at the Shangri-La Hotel in Colombo. The Summit, under the theme “Shaping Sri Lanka’s Future: Transformational Growth Rooted in Sound Economic Policies,” is set to bring together a distinguished lineup of national and international industry leaders, policymakers, and experts to discuss the country’s economic future. As Sri Lanka continues to navigate through significant political and economic changes, the Summit aims to provide critical insights into the policies needed to foster an export-led growth model. The discussions will focus on unlocking the country’s export potential, leveraging its strategic location, and accessing fast-growing regional markets. The summit will also emphasize the reforms required to boost key sectors, such as Tourism, Agriculture, and Value-Added Manufacturing, in driving sustainable and inclusive growth. Over the course of two days, participants will engage in high-level panel discussions, breakout sessions, and networking opportunities designed to address key challenges and opportunities for Sri Lanka’s economic development. Among the key topics to be explored are policies for improving export competitiveness, attracting foreign investment, and implementing structural reforms across sectors that can shape the nation’s future growth. Since its inception in 2020, the Sri Lanka Economic Summit has become a premier platform for thought leadership, attracting some of the brightest minds in industry, policy, and academia. It continues to play a crucial role in shaping the nation’s economic discourse and facilitating dialogue between the public and private sectors. Registration for the 2025 Summit is now open, and with seats filling up fast, participants are encouraged to secure their places early to avoid disappointment. For more details and registration, visit SLES Registration. For further inquiries, contact Alikie at 011-5588805 or via email at alikie@chamber.lk.